摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-bromo-8-methoxy-3,4-dihydroisoquinoline | 1257243-49-4

中文名称
——
中文别名
——
英文名称
5-bromo-8-methoxy-3,4-dihydroisoquinoline
英文别名
5-Bromo-3,4-dihydro-8-methoxyisoquinoline
5-bromo-8-methoxy-3,4-dihydroisoquinoline化学式
CAS
1257243-49-4
化学式
C10H10BrNO
mdl
——
分子量
240.099
InChiKey
SVNFURWVLWCMDJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    21.6
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    5-bromo-8-methoxy-3,4-dihydroisoquinoline 在 aluminum (III) chloride 作用下, 以 氯苯 为溶剂, 反应 1.5h, 以97%的产率得到5-bromo-3,4-dihydroisoquinolin-8-ol
    参考文献:
    名称:
    QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids
    摘要:
    Naphthylisoquinoline alkaloids have attracted considerable interest because of their intriguing structure, their unique biosynthetic origin, and their biological activities against several pathogens causing tropical diseases. Their promising pharmacologic properties make them suitable lead structures for new agents, in particular against malaria. Since these natural products are not easy to isolate in sufficient quantities or to synthesize stereoselectively, quantitative structure activity relationship studies were accomplished to find new antiplasmodial analogs that are structurally related to the naturally occurring naphthylisoquinoline alkaloids, but more easily accessible, more active against Plasmodium falciparum, and, last but not least, less toxic. We report on the synthesis of several simplified compounds by a Suzuki coupling between the naphthalene and the isoquinoline moieties and on their activities against different pathogens causing infectious diseases. Some structures were found to exhibit excellent and selective activities against P. falciparum in vitro. (C) 2010 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2010.08.062
  • 作为产物:
    描述:
    N-(2-bromo-5-methoxyphenethyl)formamide 在 polyphosphoric acid 作用下, 反应 4.0h, 以52%的产率得到5-bromo-8-methoxy-3,4-dihydroisoquinoline
    参考文献:
    名称:
    QSAR guided synthesis of simplified antiplasmodial analogs of naphthylisoquinoline alkaloids
    摘要:
    Naphthylisoquinoline alkaloids have attracted considerable interest because of their intriguing structure, their unique biosynthetic origin, and their biological activities against several pathogens causing tropical diseases. Their promising pharmacologic properties make them suitable lead structures for new agents, in particular against malaria. Since these natural products are not easy to isolate in sufficient quantities or to synthesize stereoselectively, quantitative structure activity relationship studies were accomplished to find new antiplasmodial analogs that are structurally related to the naturally occurring naphthylisoquinoline alkaloids, but more easily accessible, more active against Plasmodium falciparum, and, last but not least, less toxic. We report on the synthesis of several simplified compounds by a Suzuki coupling between the naphthalene and the isoquinoline moieties and on their activities against different pathogens causing infectious diseases. Some structures were found to exhibit excellent and selective activities against P. falciparum in vitro. (C) 2010 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2010.08.062
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLYLE ET LEUR UTILISATION COMME MODULATEURS DE RÉCEPTEURS DE LA PROSTAGLANDINE D2
    申请人:ACTELION PHARMACEUTICALS LTD
    公开号:WO2013093842A1
    公开(公告)日:2013-06-27
    The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I) wherein Z, n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    本发明涉及式(I)的苯基取代杂环基衍生物,其中Z、n、m、R1、R2、R3、R4、R5、R6、R7和R8如描述中所述,并且它们作为前列腺素受体调节剂的用途,尤其作为前列腺素D2受体调节剂,在治疗各种前列腺素介导的疾病和紊乱中的用途,以及含有这些化合物的药物组合物和其制备方法。
  • Heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:US09255090B2
    公开(公告)日:2016-02-09
    The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Z, n, m, R1, R2, R3, R4, R5, R6, R7 and R8 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    本发明涉及公式(I)的苯基取代的杂环基衍生物,其中Z,n,m,R1,R2,R3,R4,R5,R6,R7和R8如描述中所述,以及它们在各种前列腺素介导的疾病和障碍的治疗中作为前列腺素受体调节剂的用途,特别是作为前列腺素D2受体调节剂,以及包含这些化合物的制药组合物和它们的制备方法。
  • Heterocyclyl Derivatives and their use as Prostaglandin D2 Receptor Modulators
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:US20150252036A1
    公开(公告)日:2015-09-10
    The present invention relates to phenyl-substituted heterocyclyl derivatives of the formula (I), wherein Z, n, m, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are as described in the description and their use as prostaglandin receptor modulators, most particularly as prostaglandin D 2 receptor modulators, in the treatment of various prostaglandin-mediated diseases and disorders, to pharmaceutical compositions containing these compounds and to processes for their preparation.
    本发明涉及公式(I)的苯基取代杂环基衍生物,其中Z,n,m,R1,R2,R3,R4,R5,R6,R7和R8如描述中所述,并且它们作为前列腺素受体调节剂的用途,特别是作为前列腺素D2受体调节剂,在治疗各种前列腺素介导的疾病和疾患中使用,以及包含这些化合物的制药组合物和它们的制备过程。
  • HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS
    申请人:Actelion Pharmaceuticals Ltd.
    公开号:EP2794563A1
    公开(公告)日:2014-10-29
  • US9255090B2
    申请人:——
    公开号:US9255090B2
    公开(公告)日:2016-02-09
查看更多

同类化合物

鼻通 诺斯卡品杂质2 美莫汀盐酸盐 美莫汀 法莫汀盐酸盐 氯化可替宁 异喹啉,3,4-二氢-6,7-二甲氧基-3,3-二甲基- 异喹啉,3,4-二氢-6,7-二甲氧基-1-苯基-,盐酸 异喹啉,3,4-二氢-5,6,7-三甲氧基-1-甲基- 丁-2-烯二酸;7-甲基-3-[(4-甲基哌嗪-1-基)甲基]-1-苯基-3,4-二氢异喹啉 7-苄氧基-6-甲氧基-3,4-二氢异吲哚 7-羟基-6-甲氧基-3,4-二氢异喹啉 7-硝基-3,4-二氢异喹啉 7-甲基-3,4-二氢异喹啉 7-溴二氢异喹啉 7-溴-3,4-二氢异喹啉盐酸盐 7-溴-1-异丙基-3,4-二氢异喹啉 7-氯-1-苯基-3,4-二氢异喹啉 7-氟-3,4-二氢异喹啉 7-氟-1-甲基-3,4-二氢异喹啉 7,8-二甲氧基-3,4-二氢异喹啉 7,8-二氢-[1,3]二氧代[4,5-g]异喹啉 7,8-二氢-5-[4-(异丙基磺酰基)苯基]-1,3-二氧杂环戊并[4,5-g]异喹啉 6-苄氧基-7-甲氧基-3,4-二氢-异喹啉 6-羟基-7-甲氧基-2-甲基-3,4-二氢异喹啉正离子 6-甲氧基-3,4-二氢-异喹啉 6-甲氧基-1-甲基-3,4-二氢异喹啉 6-氯-1-(2-氯-苯基)-7-甲氧基-3,4-二氢-异喹啉 6-氯-1-(2-异丙基-苯基)-7-甲氧基-3,4-二氢-异喹啉 6-氯-1-(2,6-二甲基-苯基)-7-甲氧基-3,4-二氢-异喹啉 6-氟-3,4-二氢异喹啉 6,7-二甲氧基-3-甲基-3,4-二氢异喹啉盐酸盐 6,7-二甲氧基-3,4-二氢异喹啉盐酸盐 6,7-二甲氧基-3,4-二氢异喹啉 6,7-二甲氧基-1-(4-甲氧基苯基)-3,4-二氢异喹啉 6,7-二甲氧基-1-(3,4-二甲氧基苯基)-3-羟基甲基-3,4-二氢异喹啉 6,7-二甲氧基-1,3,3-三甲基-3,4-二氢异喹啉氢碘化 6,7-二甲-1,3-二甲基-3,4-二氢异喹啉盐酸盐 6,7-二乙氧基-3,4-二氢异喹啉盐酸盐 5-甲氧基-1-甲基-3,4-二氢异喹啉 5-甲基吡咯-3-腈 5-甲基-7,8-二氢-[1,3]二氧戊环并[4,5-G]异喹啉 5-甲基-3,4-二氢-异喹啉 5-氯-2-(6,7-二甲氧基-3,4-二氢异喹啉-1-基)苯胺 5,8-二甲氧基-3-甲基-3,4-二氢-异喹啉 4-甲氧基-7,8-二氢[1,3]二氧杂环戊并[4,5-g]异喹啉 4-甲氧基-6-甲基-7,8-二氢[1,3]二氧杂环戊并[4,5-g]异喹啉-6-鎓碘化物 4-氯-2-(6,7-二甲氧基-3,4-二氢异喹啉-1-基)苯胺 4-(6,7-二甲氧基-3,4-二氢异喹啉-1-基)庚二腈 4-(3,4-二氢异喹啉-1-基)苯甲腈